The Episilvestrol and Bortezomib combination potently induces CRC cell killing with very little or no reduction in well-established eiF4E oncotargets such as c-Myc, Bcl-xL or its regulators such as p-4E-BP1 (37/46) or p-AKT [6, 7], distinct from that induced by single agent at much higher doses. This evidence concerns the gene AKT1 and colorectal carcinoma.